8-K current report · filed Aug 17, 2026

EyePoint, Inc. (EYPT) 8-K Current Report: August 17, 2026

Item 8.01Item EX-99.1Item EX-99.2EYPT overview

Short answer

EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Topline LUGANO Phase 3 data announced for DURAVYU in wet AMD.

EyePoint, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Topline LUGANO Phase 3 data announced for DURAVYU in wet AMD
  • Results represent a pivotal clinical milestone with potential regulatory and commercial implications
  • Updated investor presentation provides additional program context and outlook
  • Detailed efficacy and safety results are in Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • LUGANO’s full-dataset primary endpoint failed, creating regulatory and investor risk despite favorable secondary outcomes
  • Ad hoc analysis excluding 9 of 211 patients with unrelated vision loss showed non-inferiority versus aflibercept, nominal p=0.0096
  • DURAVYU reduced treatment burden 42%, equivalent to two fewer injections through Week 56 versus aflibercept
  • 54% remained supplement-free through Week 56, while 79% received zero or one supplement
  • LUCIA topline data expected Q4 2026, with potential NDA submission targeted for 1H 2027

Item EX-99.2 · Exhibit EX-99.2

  • LUGANO missed its full-set BCVA non-inferiority endpoint, a major regulatory risk despite favorable secondary results
  • Excluding 9 DURAVYU patients with non-wet-AMD vision loss, non-inferiority achieved at nominal p=0.0096
  • Treatment burden fell 42% versus aflibercept, with nominal p<0.0001 and 54% supplement-free through Week 56
  • Anatomic control remained strong, with only a 4-micron CST difference versus aflibercept through Week 56
  • LUCIA topline data expected Q4 2026, followed by a potential FDA NDA submission in H1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other EyePoint, Inc. 8-K filings

Get the next EYPT 8-K as it lands

Follow EYPT for push alerts, or ask the research agent what this filing means.